Background: Brain-gut interaction involves, among others, peptidergic
growth factors which are native in GI tract and have strong antiulcer potency and
thus could from periphery beneficially affect CNS-disorders. We focused on the
stable gastric pentadecapeptide BPC 157, an antiulcer peptidergic agent, safe in
inflammatory bowel disease trials and now in multiple sclerosis trial, native and
stable in human gastric juice.
Methods: Review of our research on BPC 157 in terms of brain-gut axis.
Results: BPC 157 may serve as a novel mediator of Robert’s cytoprotection, involved
in maintaining of GI mucosa integrity, with no toxic effect. BPC 157 was successful
in the therapy of GI tract, periodontitis, liver and pancreas lesions, and in the healing of various tissues
and wounds. Stimulated Egr-1 gene, NAB2, FAK-paxillin and JAK-2 pathways are hitherto implicated.
Initially corresponding beneficial central influence was seen when BPC 157 was given peripherally and a
serotonin release in particular brain areas, mostly nigrostriatal, was changed. BPC 157 modulates
serotonergic and dopaminergic systems, beneficially affects various behavioral disturbances that
otherwise appeared due to specifically (over)stimulated/damaged neurotransmitters systems. Besides,
BPC 157 has neuroprotective effects: protects somatosensory neurons; peripheral nerve regeneration
appearent after transection; after traumatic brain injury counteracts the otherwise progressing course, in
rat spinal cord compression with tail paralysis, axonal and neuronal necrosis, demyelination, cyst
formation and rescues tail function in both short-terms and long-terms; after NSAIDs or insulin overdose
or cuprizone encephalopathies were attenuated along with GI, liver and vascular injuries.
Conclusion: BPC 157, a gastric peptide, may serve as remedy in various CNS-disorders.